GSK‐3β inhibitors hold therapeutic potentials for T2DM and AD possibly by preventing the aggregation of β‐amyloid (Aβ), inhibiting the hyperphosphorylation of tau protein, or reducing neuroinflammation in animal models,47, 48, 49, 50 but their effectiveness for improving cognitive impairment need further proof. This evidence concerns the gene MAPT and Alzheimer disease.